had been audited by the independent auditor. Details are as follows: 1. Main events of the Company 2. Summary of the Company’s operating results 3. Analysis of the consolidated financial performance 4
. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public
Financial performances Comparison is as follows: THB’000 Consolidated ∆% Separate ∆% Q1/2019 Q1/2018 Q1/2018 Q1/2017 Revenues from sales and services of medical equipment 460,711 366,698 26% 382,283 320,648
declined yoy whereas revenue per head remained on the rise. The increase of revenue per head was Operation : Consolidated Profit & Loss Statement 3Q 3Q % 9 mth 9 mth % Unit : THB million 2019 2018 change
follows: Statements of Comprehensive Income for the 1st Quarter Ended March 31, 2020 Revenue from Hospital Operations Operation : Consolidated Profit & Loss Statement 1Q 1Q % Unit : THB million 2020 2019
statement for the 3-month and 6-month period ended June 30, 2018, details are as follows: The operating results of the consolidated financial statement for the 3-month and 6-month period ended June 30, 2018
Company Limited (“the Company”) reported consolidated operating revenue of THB 198 million in Q1/2022 and THB 179 million in Q1/2021, increased by 11%, mainly due to the revenue growth from dessert café as
financial position for the fourth quarter and year ended December 31, 2019 with those of 2018. This report discusses principal changes in the audited consolidated financial statements. Overall market
mobile ARPU improvement as well as an increasing number of fixed broadband customers. Sales revenue was Bt7,488mn, a decrease 9.9% YoY from softened competition but rose 49% QoQ due to seasonality. Sales
Page 1 of 6 Performance Overview In 2017 Singha Estate Public Company Limited (“the Company” or “Singha Estate”) reported a consolidated net profit of Bt572mn, representing a growth of 236% YoY with